News and Press Releases
Press releases
Theralase® to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
V.TLT | March 26th, 2024 Toronto, Ontario – March 26th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) ...
0Theralase® Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson’s Disease
V.TLT | February 12th, 2024 Toronto, Ontario – February 12th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OT...
0Dr. Michael Jewett Joins Theralase® to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
V.TLT | February 8th, 2024 Toronto, Ontario – February 8th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQ...
0Theralase® Closes $CAN 1.2 Million Non-Brokered Private Placement
V.TLT | February 5th, 2024 Toronto, Ontario – February 5th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company“) (TSXV:TLT) (OTCQ...
0
Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Toronto, Ontario – January 15th, 2024, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV:TLT) (OTCQB:TLTFF), a clinica...
0
Theralase Release’s 3Q2023 Interim Financial Statements
Toronto, Ontario – November 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clin...
0Theralase® Closes $CAN 1.17 Million Non-Brokered Private Placement
November 29, 2023, Theralase® successfully closed a non-brokered private placement offering of units for gross proceeds of approximately $CAN...
0Theralase® Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario – November 17, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinic...
0Theralase® Announces Brokered LIFE Financing
Toronto, Ontario – October 23, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinica...
0
Theralase® Provides Update on Bladder Cancer Clinical Study
Theralase®’s Latest Clinical Data Demonstrates 65% of Patients Treated with Theralase®’s Anti-Cancer Therapy Achieved a Complete Response Tor...
0in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
